Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

被引：2

作者：

Stepan, Lara ^{[1
]}

Ansari, Sahar ^{[1
]}

Okal, Abood ^{[2
]}

Dell'Aringa, Justine ^{[1
]}

Thompson, Ethan ^{[1
]}

Crotta, Alessandro ^{[3
]}

Chow, Victor A. ^{[1
]}

Abramson, Jeremy S. ^{[4
]}

Kamdar, Manali ^{[5
]}

Chabon, Jacob J. ^{[6
]}

Hogan, Gregory ^{[6
]}

Kurtz, David M. ^{[7
]}

Alizadeh, Ash A. ^{[8
]}

Peiser, Leanne ^{[1
]}

机构：

[1] Bristol Myers Squibb, Seattle, WA USA

[2] Bristol Myers Squibb, Princeton, NJ USA

[3] Celgene, Boudry, Switzerland

[4] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[5] Univ Colorado, Canc Ctr, Aurora, CO USA

[6] Foresight Diagnost, Aurora, CO USA

[7] Stanford Univ, Div Hematol & Oncol, Dept Med, Stanford, CA USA

[8] Stanford Univ, Stanford Canc Inst, Stanford, CA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-181007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
Abramson, Jeremy S.
Solomon, Scott R.
Arnason, Jon
Johnston, Patrick B.
Glass, Bertram
Bachanova, Veronika
Ibrahimi, Sami
Mielke, Stephan
Mutsaers, Pim
Hernandez-Ilizaliturri, Francisco
Izutsu, Koji
Morschhauser, Franck
Lunning, Matthew
Crotta, Alessandro
Montheard, Sandrine
Previtali, Alessandro
Ogasawara, Ken
Kamdar, Manali
BLOOD, 2023, 141 (14) : 1675 - 1684
[2] Lisocabtagene maraleucel in second-line large B-ell lymphoma: Primary analysis of phase 3 TRANSFORM study
Davies, Andrew
Abramson, Jeremy S.
Solomon, Scott R.
Arnason, Jon
Johnston, Patrick B.
Glass, Bertram
Bachanova, Veronika
Ibrahimi, Sami
Mielke, Stephan
Mutsaers, Pim
Hernandez-Ilizaliturri, Francisco
Izutsu, Koji
Morschhauser, Franck
Lunning, Matthew
Crotta, Alessandro
Montheard, Sandrine
Previtali, Alessandro
Ogasawara, Ken
Kamdar, Manali
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 10 - 11
[3] FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma
Elmacken, Mona
Peredo-Pinto, Helkha
Wang, Cong
Xu, Zhenzhen
Tegenge, Million
Jaigirdar, Adnan A.
Theoret, Marc R.
Purohit-Sheth, Tejashri
Kasamon, Yvette L.
CLINICAL CANCER RESEARCH, 2024, 30 (11) : 2309 - 2316
[4] Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study
Gordon, Leo I.
Liu, Fei Fei
Braverman, Julia
Hoda, Daanish
Ghosh, Nilanjan
Hamadani, Mehdi
Hildebrandt, Gerhard C.
Peng, Lily
Guo, Shien
Shi, Ling
Sehgal, Alison
HAEMATOLOGICA, 2024, 109 (03) : 857 - 866
[5] Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study
Lee, Dasom
Sworder, Brian J.
Stepan, Lara
Okal, Abood
Huang, Chang-Pin
Kang, Xiaoman
Hamilton, James
Macaulay, Charles
Olsen, Mari
Liu, Chih Long
Diehn, Maximilian
Peiser, Leanne
Kurtz, David
Alizadeh, Ash A.
BLOOD, 2024, 144 : 3412 - 3412
[6] Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study
Sehgal, Alison R.
Hoda, Daanish
Riedell, Peter A.
Ghosh, Nilanjan
Hamadani, Mehdi
Hildebrandt, Gerhard
Godwin, John E.
Reagan, Patrick M.
Wagner-Johnston, Nina
Essell, James
Nath, Rajneesh
Solomon, Scott R.
Champion, Rebecca
Licitra, Edward
Fanning, Suzanne
Gupta, Neel K.
Chow, Victor A.
Yuan, Brenda
Yang, Zhi
Ogasawara, Ken
Thorpe, Jerill
Gordon, Leo I.
BLOOD, 2023, 142
[7] Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
Kurtz, David M.
Scherer, Florian
Jin, Michael C.
Soo, Joanne
Craig, Alexander F. M.
Esfahani, Mohammad Shahrokh
Chabon, Jacob J.
Stehr, Henning
Liu, Chih Long
Tibshirani, Robert
Maeda, Lauren S.
Gupta, Neel K.
Khodadoust, Michael S.
Advani, Ranjana H.
Levy, Ronald
Newman, Aaron M.
Duehrsen, Ulrich
Huettmann, Andreas
Meignan, Michel
Casasnovas, Rene-Olivier
Westin, Jason R.
Roschewski, Mark
Wilson, Wyndham H.
Gaidano, Gianluca
Rossi, Davide
Diehn, Maximilian
Alizadeh, Ash A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2845 - +
[8] COST-EFFECTIVENESS ANALYSIS OF SECOND-LINE TREATMENT WITH LISOCABTAGENE MARALEUCEL VERSUS STANDARD OF CARE FOR PATIENTS WITH LARGE B-CELL LYMPHOMA IN THE NETHERLANDS
Buisman, L.
Elsada, A.
Klijn, S.
Chavan, A.
Pham, H. A.
Sillem, E.
Deger, K.
van Beekhuizen, S.
Pompen, M.
Foo, J.
VALUE IN HEALTH, 2024, 27 (12) : S73 - S73
[9] Subgroup analyses of primary refractory vs early relapsed Large B-cell Lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs Standard of Care (SOC) as second-line (2L) therapy
Glass, B.
Nastoupil, L.
Kamdar, M.
Chavez, J. C.
Ghesquieres, H.
Ghosh, M.
Holmes, H.
Lopez-Guillermo, A.
Martinez-Lopez, J.
Novak, U.
Ribrag, V
Roddie, C.
Waller, E. K.
Feldman, T.
Rosenthal, A. C.
Sauter, C.
von Bonin, M.
Karmali, R.
Montheard, S.
Previtali, A.
Abramson, J.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 210 - 211
[10] Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
Sehgal, Alison
Hoda, Daanish
Riedell, Peter A.
Ghosh, Nilanjan
Hamadani, Mehdi
Hildebrandt, Gerhard C.
Godwin, John E.
Reagan, Patrick M.
Wagner-Johnston, Nina
Essell, James
Nath, Rajneesh
Solomon, Scott R.
Champion, Rebecca
Licitra, Edward
Fanning, Suzanne
Gupta, Neel
Dubowy, Ronald
D'Andrea, Aleco
Wang, Lei
Ogasawara, Ken
Thorpe, Jerill
Gordon, Leo, I
LANCET ONCOLOGY, 2022, 23 (08): : 1066 - 1077

← 1 2 3 4 5 →